You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君实生物(01877.HK)就新冠病毒抗体与礼来制药签合作
阿思达克 05-04 09:10
君实生物(01877.HK)公布,公司与美国礼来制药公司签署了《研发合作和许可协议》。根据协议,双方将合作研发及商业化SARS-CoV-2中和抗体(君实新冠抗体,产品代号JS016),并且礼来制药将被授予在大中华地区(包括中国大陆、香港地区、澳门地区及台湾地区)外对君实新冠抗体开展研发活动、生产和销售的独占许可。

礼来制药将向公司支付1,000万美元首付款,并在每一个君实新冠抗体实现规定的里程碑事件後,向公司支付最高2.45亿美元的里程碑款,外加该产品销售净额两位数百分比的销售分成。另礼来制药承诺按照双方同意的条款和条件,以7,500万美元认购公司新发行的H股股份,潜在认购尚待订立一份正式认购协议。

JS016是一款重组全人源单克隆中和抗体,特异性结合SARS-CoV-2表面刺突蛋白受体结构域,并能有效阻断病毒与宿主细胞表面受体ACE2的结合。该项目由公司与中国科学院微生物研究所共同开发。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account